Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 316-326

  Hammond Thelin, Lisa A ^a   Thomas, Melanie B ^b   Iwasaki, Michiko ^b   Abbruzzese, James L ^b   Lassere, Yvonne ^b   Meyers, Christina A ^b   Hoff, Paulo ^b   De Bono, Johann ^a   Norris, Jody ^a   Matsushita, Hitoshi ^c   Mita, Akira ^c   Rowinsky, Eric K ^a,d  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d NONE   (United States)

Author keywords

Nucleoside; Pharmacokinetics; Phase 1; Pyrimidine; TAS 106

Indexed keywords

3' ETHYNYLCYTIDINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; FEVER; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; VOMITING;

EID: 84856510639     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9535-y     Document Type: Article

References (51)

1. Schiller G, Gajewski J, Territo M et al (1992) Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80:2977-2982 (Pubitemid 23004500)
2. Yates J, Gildwell O, Wiernik P et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60:454-462 (Pubitemid 12048693)
3. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130 (Pubitemid 30036345)
4. Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
5. Ohno Y, Spriggs D, Matsukage A, Ohno T, Kufe D (1988) Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β. Cancer Res 48:1494-1498 (Pubitemid 18091195)
6. Mikita T, Beardsley GP (1988) Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry 27:4698-4705
7. Fram RJ, Kufe DW (1982) DNA strand breaks caused by inhibitors of DNA synthesis: 1-β-D-arabinofuranosylcytosine and aphidicolin. Cancer Res 42:4050-4053 (Pubitemid 13198563)
8. Ross DD, Cuddy DP, Cohen N, Hensley DR (1992) Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-β-D- arabinofuranosylcytosine. Cancer Chemother Pharmacol 31:61-70
9. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GF (1993) 2', 2'-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 46:762-766 (Pubitemid 23262974)
10. Carmichael J, Possinger K, Phillip P (1995) Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736
11. Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184 (Pubitemid 24062575)
12. Tabata S, Tanaka M, Matsuda A, Fukushima M, Sasaki T (1996) Antitumor effect of a novel multifunctional antitumor nucleoside, 3'-ethynylcytidine, on human cancers. Oncol Rep 3:1029-1034 (Pubitemid 26355171)
13. Fukushima M (1998) The new antitumor ribonucleoside 3'-Cethynylcytidine: Its antitumor effects and mechanism of action. Purine Pyrimidine Metab 22:189-199
14. Mattern MR, Fecteau DA, Sung CM, Fisher PW, Johnson RK, Winkler JD (200) Ecyd is an inhibitor of RNA polymerase which induces apoptosis without activation of the DNA damage checkpoint. Clin Cancer Res 6:4554s,440a.
15. Azuma A, Emura T, Huang P, Plunkett W (1999) Intracellular metabolism and actions of a novel antitumor nucleoside, 1-(3'-Cethynyl- β-D-ribo- pentofuranosyl) cytosine (Ecyd, TAS-106). Proc Am. Assoc Cancer Res 40:298,1975a
16. Takatori S, Kanda H, Takenaka K (2000) Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1- (3-C-ethynyl-β- D-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol 44:97-104
17. Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A (1996) Nucleosides and Nucleotides. 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)- cytosine, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil, and their nucleobase analgoues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39:5005-5011 (Pubitemid 26422516)
18. Tsuji A, Tami I, Saheki A (1999) Facilitative transport of antitumor nucleosides, 3'-ethynylcytidine (ECyd, TAS-106) and 3'-ethynyluridine (EUrd). Proc Am Assoc Cancer Res 40:298, 1977a
19. Tanaka M, Sasaki T (2000) Cellular uridine/cytidine kinsae (U/C kinase) as a promising predictor of a novel nucleoside 3'-ethynylcytidine sensitivity. Proc NCI-EORTC-AACR 11:4554S, 441a
20. TAS-106 Investigator Brochure. Tokyo, Japan. Taiho Pharmaceutical Co., Ltd. 2001
21. Shimamoto Y, Murukami Y, Kazuno H et al (1999) Effect of the TAS-106 (3'-C-ethynylcytidine, ECyd) dosage schedule on antitumor efficacy in experimental human cancer. Proc Am Assoc Cancer Res 40:298,1979a
22. Zubrod CG, Schneiderman M, Frei E (1960) Appraisal methods for the study of chemotherapy of cancer in man: Comparative therapeutic trials of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7-33
23. Guidelines for Reporting of Adverse Drug Reactions, Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: National Cancer Institute, 1988
24. Matsuoka K, Kitamura R, Matsushima E, Kawaguchi Y (2003) Determination of 3'-C-ethynylcytidine in human plasma and urine by liquid chromatographic- electroscopy ionization tandem mass spectrometry. J Pharm Biomed Anal 31:47-55 (Pubitemid 36120618)
25. Hashimoto T (2001) Statistical evaluation of pharmacokinetics linearity in clinical pharmacological study. Xenobio Metabol Dispos 16:244-252
26. Estey EH, Thall PF, Pierce S et al (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- alltrans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478-2484 (Pubitemid 29181178)
27. Burnett AK (1999) Tailoring the treatment of acute myeloid leukemia. Curr Opin Hematol 6:247-252 (Pubitemid 29380465)
28. McCarthy AJ, Pitcher LA, Hann IM, Oakhill A (1999) FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol 32:411-415 (Pubitemid 29249740)
29. Lund B, Ryberg M, Petersen P, Anderson H, Thatcher N, Dombernowsky P (1994) Phase II study of gemcitabine (2', 2'- difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 5:852-853 (Pubitemid 24341881)
30. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A Phase II study. J Clin Oncol 12:1535-1540 (Pubitemid 24244986)
31. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced nonsmall- cell lung cancer: A Phase II study. J Clin Oncol 12:1821-1826 (Pubitemid 24349383)
32. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2', 2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533 (Pubitemid 24330217)
33. Jeha S, Razzouk B, Gaynon P (2004) Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. Proc Am Soc Clin Oncol 23:796,8504a
34. Russell JA, Powles RL (1974) Neuropathy due to cytosine arabinoside. Br Med J 4:652-653
35. Borgeat A, DeMuralt B, Stalder M (1986) Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 58:852-854 (Pubitemid 16035282)
36. Thomas M, Mita A, Hammond L, et al (2002) A phase I and pharmacokinetic study of TAS-106 administered weekly for 3 consecutive weeks every 28 days in patients with solid tumors. Eur J Cancer 38:S25,67a
37. Cho ES, Spencer PS, Jortner BS, Schaumburg HH (1980) A single intravenous injection of doxorubicin (Adriamycin) induces sensory neuropathy in rats. NeuroToxicology 1:583-591 (Pubitemid 10134679)
38. Cho ES (1977) Toxic effects of Adriamycin on the ganglia of the peripheral nervous system: A neuropathological study. J Neuropathol Exp Neurol 36:907-915 (Pubitemid 8238367)
39. Anthony DC, Montine TJ, Graham DG (1997) Toxic responses of the nervous system, neuronopathies, casarett and doull's toxicology. In: Klaassen CD (ed) The basic science of poisons, 5th edn, pp 467-470
40. Megumi T et al (1977) Drug induced sensory impairment: Mode of peripheral neuropathy that is based on the site of primary impairment in the lesions. Brain and Neuroscience Drug Induced Neuropathy 5:98-102
41. Smith B (1969) Damage to the intrinsic cardiac neurones by rubidomycin (daunorubicin). Br Heart J 31:607-609
42. de Bono JS, Stephenson J Jr, Baker SD et al (2002) Troxacitabine, an L-steroisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 20:96-109 (Pubitemid 34032601)
43. Giles GJ, Cortes JE, Baker SD et al (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19:762-771 (Pubitemid 32119091)
44. Townsley CA, Chi K, Ernst DS et al (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21:1524-1529 (Pubitemid 46594105)
45. Dent SF, Arnold A, Stewart D, et al (2001) Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:259b, 2768a
46. Belanger K, Moore M, Baker SD et al (2002) Phase I and pharmacokinetic study of a novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 20:2567-2574 (Pubitemid 34525745)
47. Meyers CA, Byrne KS, Komaki R (1995) Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231-235
48. van Dam FSAM, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218 (Pubitemid 28114539)
49. Pavol M, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M (1995) Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 45:947-950
50. Capizzi RL, Yang JL, Cheng E et al (1983) Alterations of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1:763-771 (Pubitemid 14167250)
51. Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:S3-S15